India's curb on Covid jab exports 'problematic' for Africa: official

Published
0

India's decision to slow coronavirus vaccine exports will make it difficult for Africa to hit its year-end vaccination goal, the head of the continent's disease control body has said.

Oxford/AstraZeneca jabs produced by the Serum Institute of India represent the “backbone” of Africa's own vaccination campaign, John Nkengasong, director of the Africa Centres for Disease Control and Prevention (Africa CDC), told a press conference, according to AFP.

The majority of the continent's doses have so far come from the Covax scheme, which aims to provide equitable access around the world and particularly in poorer countries.

“If those are delayed then we are unlikely to meet our targets,” Nkengasong said. “If the delay continues — and I really want to deliberately hope that it is a delay, not a ban because that would be catastrophic if that was the case — then meeting our vaccination schedule becomes problematic, very very problematic.”

Opinion

Editorial

Yemen offensive
Updated 04 Oct, 2026

Yemen offensive

The best option, therefore, is for Muslim and Arab states to help restore the Saudi-Houthi ceasefire.
Growth transition
04 Oct, 2026

Growth transition

PRIME Minister Shehbaz Sharif’s recent call to move from stabilisation to growth, job creation and export ...
Protection at risk
04 Oct, 2026

Protection at risk

THE recent warning from UNHCR should alarm donor governments. Nearly 8.3m refugees and other forcibly displaced...
Talks, at last
Updated 03 Oct, 2026

Talks, at last

The government’s constant threats to suspend KP’s elected dispensation over a political protest have escalated hostilities considerably. In that context, both sides did well to start talking.
IWT’s future
Updated 03 Oct, 2026

IWT’s future

TOGETHER with the Kashmir dispute, India’s unilateral suspension of the Indus Waters Treaty has become the biggest...
Pained minds
03 Oct, 2026

Pained minds

IN Pakistan, mental healthcare is wedged between two extremes — a luxury or a stigma. Estimates cited by the...